214 related articles for article (PubMed ID: 24503346)
1. ¹⁷⁷Lu-EDTMP for treatment of bone pain in patients with disseminated skeletal metastases.
Shinto AS; Shibu D; Kamaleshwaran KK; Das T; Chakraborty S; Banerjee S; Thirumalaisamy P; Das P; Veersekar G
J Nucl Med Technol; 2014 Mar; 42(1):55-61. PubMed ID: 24503346
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of 177Lu-EDTMP in bone metastatic pain palliation in breast cancer and hormone refractory prostate cancer: a phase II study.
Yuan J; Liu C; Liu X; Wang Y; Kuai D; Zhang G; Zaknun JJ
Clin Nucl Med; 2013 Feb; 38(2):88-92. PubMed ID: 23334120
[TBL] [Abstract][Full Text] [Related]
3. Clinical Efficacy and Safety Comparison of 177Lu-EDTMP with 153Sm-EDTMP on an Equidose Basis in Patients with Painful Skeletal Metastases.
Thapa P; Nikam D; Das T; Sonawane G; Agarwal JP; Basu S
J Nucl Med; 2015 Oct; 56(10):1513-9. PubMed ID: 26315829
[TBL] [Abstract][Full Text] [Related]
4.
Askari E; Harsini S; Vahidfar N; Divband G; Sadeghi R
Cancer Biother Radiopharm; 2021 Jun; 36(5):383-390. PubMed ID: 33259726
[No Abstract] [Full Text] [Related]
5. Formulation, preclinical evaluation, and preliminary clinical investigation of an in-house freeze-dried EDTMP kit suitable for the preparation of 177Lu-EDTMP.
Das T; Sarma HD; Shinto A; Kamaleshwaran KK; Banerjee S
Cancer Biother Radiopharm; 2014 Dec; 29(10):412-21. PubMed ID: 25409337
[TBL] [Abstract][Full Text] [Related]
6. Prospective evaluation of samarium-153-EDTMP radionuclide treatment for bone metastases in patients with hormone-refractory prostate cancer.
Dolezal J; Vizda J; Odrazka K
Urol Int; 2007; 78(1):50-7. PubMed ID: 17192733
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and toxicity of 153samarium-EDTMP in painful breast cancer bone metastases.
Dolezal J
Onkologie; 2009 Feb; 32(1-2):35-9. PubMed ID: 19209017
[TBL] [Abstract][Full Text] [Related]
8. (177)Lu-EDTMP for palliation of pain from bone metastases in patients with prostate and breast cancer: a phase II study.
Agarwal KK; Singla S; Arora G; Bal C
Eur J Nucl Med Mol Imaging; 2015 Jan; 42(1):79-88. PubMed ID: 25070686
[TBL] [Abstract][Full Text] [Related]
9. Our experience on pain palliation of bone metastasis with Sr-89 or Sm-153 in cancer patients resistant to a conventional analgesic therapy. A retrospective study.
Montesano T; Giacomobono S; Acqualagna G; Colandrea M; Di Nicola A; Travascio L; Giancamerla M; D'Apollo R; Toteda M; Ugolini F; Filesi M; Ronga G
Clin Ter; 2009; 160(3):193-9. PubMed ID: 19756320
[TBL] [Abstract][Full Text] [Related]
10. A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases.
Liepe K; Kotzerke J
Nucl Med Commun; 2007 Aug; 28(8):623-30. PubMed ID: 17625384
[TBL] [Abstract][Full Text] [Related]
11. The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain.
Liepe K; Runge R; Kotzerke J
J Cancer Res Clin Oncol; 2005 Jan; 131(1):60-6. PubMed ID: 15449184
[TBL] [Abstract][Full Text] [Related]
12. Multispecies animal investigation on biodistribution, pharmacokinetics and toxicity of 177Lu-EDTMP, a potential bone pain palliation agent.
Máthé D; Balogh L; Polyák A; Király R; Márián T; Pawlak D; Zaknun JJ; Pillai MR; Jánoki GA
Nucl Med Biol; 2010 Feb; 37(2):215-26. PubMed ID: 20152721
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic, Dosimetry and Toxicity Study of ¹⁷⁷Lu-EDTMP in Patients: Phase 0/I study.
Bal C; Arora G; Kumar P; Damle N; Das T; Chakraborty S; Banerjee S; Venkatesh M; Zaknun JJ; Pillai MR
Curr Radiopharm; 2016; 9(1):71-84. PubMed ID: 25771371
[TBL] [Abstract][Full Text] [Related]
14. Samarium-153-EDTMP: pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer.
Farhanghi M; Holmes RA; Volkert WA; Logan KW; Singh A
J Nucl Med; 1992 Aug; 33(8):1451-8. PubMed ID: 1378887
[TBL] [Abstract][Full Text] [Related]
15. Prospective evaluation of organ-specific dose and lesional doses following therapeutic [177Lu]Lu-EDTMP administration in patients with multiple skeletal metastases and its correlation with clinical hematological toxicity.
Kamaldeep ; Thapa P; Wanage G; Tervankar S; Kaisar S; Ranade R; Basu S; Das T; Banerjee S
Nucl Med Commun; 2021 Oct; 42(10):1076-1084. PubMed ID: 34528928
[TBL] [Abstract][Full Text] [Related]
16. (153)Sm-EDTMP for pain relief of bone metastases from prostate and breast cancer and other malignancies.
Correa-González L; Arteaga de Murphy C; Pichardo-Romero P; Pedraza-López M; Moreno-García C; Correa-Hernández L
Arch Med Res; 2014 May; 45(4):301-8. PubMed ID: 24681187
[TBL] [Abstract][Full Text] [Related]
17.
Alavi M; Khajeh-Rahimi F; Yousefnia H; Mohammadianpanah M; Zolghadri S; Bahrami-Samani A; Ghannadi-Maragheh M
Cancer Biother Radiopharm; 2019 Jun; 34(5):280-287. PubMed ID: 30977670
[No Abstract] [Full Text] [Related]
18. 177Lu-EDTMP: a potential therapeutic bone agent.
Ando A; Ando I; Tonami N; Kinuya S; Kazuma K; Kataiwa A; Nakagawa M; Fujita N
Nucl Med Commun; 1998 Jun; 19(6):587-91. PubMed ID: 10234664
[TBL] [Abstract][Full Text] [Related]
19. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial.
Serafini AN; Houston SJ; Resche I; Quick DP; Grund FM; Ell PJ; Bertrand A; Ahmann FR; Orihuela E; Reid RH; Lerski RA; Collier BD; McKillop JH; Purnell GL; Pecking AP; Thomas FD; Harrison KA
J Clin Oncol; 1998 Apr; 16(4):1574-81. PubMed ID: 9552068
[TBL] [Abstract][Full Text] [Related]
20. Phase 2 study of a high dose of 186Re-HEDP for bone pain palliation in patients with widespread skeletal metastases.
Pirayesh E; Amoui M; Mirzaee HR; Tabei F; Rakhsha A; Kalantari BA; Shafiei B; Assadi M; Asli IN
J Nucl Med Technol; 2013 Sep; 41(3):192-6. PubMed ID: 23918612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
